Wheeee! I am super excited because I am about to join a new clinical trial that may well save my life. As a Stage IIIC breast cancer survivor, my risk of cancer recurrence is scary sky high, and I've had two blood tests recently which both showed that my serum copper levels were above the normal range.
So my awesome, brilliant, leave-no-stone-unturned husband did his amazing research and found this groundbreaking study being done at Cornell University:
Copper depletion therapy keeps high-risk triple-negative breast cancer at bay
Triple negative breast cancer (which I don't have) is the most dangerous form, followed by the fast-growing HER2+ form, which is what I did have. This trial helps prevent the recurrence of cancer in high risk women by making them copper anemic. (Copper is highly associated with breast cancer recurrence.)
The results of six years of research were just released this week. Here's the part that's relevant to me:
[S]tudy participants with other forms of high-risk for relapse breast cancers -- either stage 3 or stage 4 ...have fared well. The progression-free survival rate among these 29 patients in the study has been 85 percent. [WOWEEEEEE! Not bad for a group of women whose survival statistics would otherwise be down in the 5-25% range. -K.A.]
The clinical trial, which began in 2007, has been expanded many times and now includes 60 patients. [And I'm about to become one of them!]